HomeCompareTSRYF vs MRK

TSRYF vs MRK: Dividend Comparison 2026

TSRYF yields 6.07% · MRK yields 2.81%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MRK wins by $26.0K in total portfolio value· pulled ahead in Year 3
10 years
TSRYF
TSRYF
● Live price
6.07%
Share price
$2.15
Annual div
$0.13
5Y div CAGR
2.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$31.7K
Annual income
$1,227.34
Full TSRYF calculator →
MRK
Merck & Co. Inc.
● Live price
2.81%
Share price
$118.10
Annual div
$3.32
5Y div CAGR
32.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57.7K
Annual income
$10,113.78
Full MRK calculator →

Portfolio growth — TSRYF vs MRK

📍 MRK pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTSRYFMRK
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TSRYF + MRK cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TSRYF pays
MRK pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TSRYF
Annual income on $10K today (after 15% tax)
$516.33/yr
After 10yr DRIP, annual income (after tax)
$1,043.24/yr
MRK
Annual income on $10K today (after 15% tax)
$238.95/yr
After 10yr DRIP, annual income (after tax)
$8,596.71/yr
At 15% tax rate, MRK beats the other by $7,553.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TSRYF + MRK for your $10,000?

TSRYF: 50%MRK: 50%
100% MRK50/50100% TSRYF
Portfolio after 10yr
$44.7K
Annual income
$5,670.56/yr
Blended yield
12.69%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on MRK right now

TSRYF
No analyst data
Altman Z
2.1
Piotroski
4/9
MRK
Analyst Ratings
24
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$128.54
+8.8% upside vs current
Range: $100.00 — $150.00
Altman Z
4.0
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TSRYF buys
0
MRK buys
8
PoliticianChamberTickerTypeAmountDate
Josh Gottheimer🏢 House$MRK▲ Buy$1,001 - $15,0002026-02-04
Michael McCaul🏢 House$MRK▼ Sell$15,001 - $50,0002026-01-13
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-12-19
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-12-18
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-11-13
Ro Khanna🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-29
Val Hoyle🏢 House$MRK▼ Sell$1,001 - $15,0002025-09-23
Marjorie Taylor Greene🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-28
Julie Johnson🏢 House$MRK▼ Sell$1,001 - $15,0002025-08-14
Gilbert Cisneros🏢 House$MRK▲ Buy$1,001 - $15,0002025-08-05
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTSRYFMRK
Forward yield6.07%2.81%
Annual dividend / share$0.13$3.32
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR2.7%32.7%
Portfolio after 10y$31.7K$57.7K
Annual income after 10y$1,227.34$10,113.78
Total dividends collected$9.1K$29.8K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TSRYF vs MRK ($10,000, DRIP)

YearTSRYF PortfolioTSRYF Income/yrMRK PortfolioMRK Income/yrGap
1$11,324$623.84$11,213$373.04+$111.00TSRYF
2$12,795$678.04$12,667$512.06+$128.00TSRYF
3← crossover$14,425$735.32$14,439$708.14$14.00MRK
4$16,231$795.73$16,640$988.16$409.00MRK
5$18,227$859.34$19,432$1,394.07$1.2KMRK
6$20,429$926.22$23,057$1,992.90$2.6KMRK
7$22,855$996.40$27,889$2,894.79$5.0KMRK
8$25,525$1,069.95$34,518$4,286.29$9.0KMRK
9$28,458$1,146.91$43,912$6,494.35$15.5KMRK
10$31,678$1,227.34$57,714$10,113.78$26.0KMRK

TSRYF vs MRK: Complete Analysis 2026

TSRYFStock

Treasury Wine Estates Limited operates as a wine company primarily in Australia, New Zealand, Asia, Europe, the Middle East, Africa, and the Americas. The company engages in the viticulture and winemaking; and marketing, sale, and distribution of wine. Its wine portfolio includes luxury, premium and commercial wine brands, such as 19 Crimes, Acacia Vineyard, Annie's Lane, Beaulieu Vineyard, Belcreme de Lys, Beringer Vineyards, Blossom Hill, Cavaliere d'Oro, Coldstream Hills, Devil's Lair, EMBRAZEN, Etude, Fifth Leg, Heemskerk, Hewitt Vineyard, Ingoldby, Jamieson's Run, Killawarra, Leo Buring, Lindeman's, Maison de Grand Esprit, Matua, Penfolds, Pepperjack, Rawson's Retreat, Rosemount Estate, Run Riot, Saltram, Samuel Wynn & Co, Secret Stone, Seppelt, Shingle Peak, Sledgehammer, Squealing pig, St Huberts, Stags' Leap Winery, Stellina di Notte, Sterling Vineyards, T'Gallant, The Walking Dead Wine, Wolf Blass, Wynns Coonawarra Estate, and Yellowglen. The company also provides contract bottling services to third parties; and sells grape and bulk wine. It owns and leases 8,362 planted hectares of vineyards in Australia and New Zealand; 2,702 planted hectares in California, including the Napa Valley, Sonoma County, Lake County, and Central Coast; 90 planted hectares in France's Bordeaux region; and 154 planted hectares in Tuscany, Italy. The company markets and sells its products to distributors, wholesalers, retails chains, independent retailers, and on-premise outlets, as well as directly to consumers. Treasury Wine Estates Limited was founded in 1843 and is headquartered in Melbourne, Australia.

Full TSRYF Calculator →

MRKHealthcare

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.

Full MRK Calculator →
📬

Get this TSRYF vs MRK comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TSRYF vs SCHDTSRYF vs JEPITSRYF vs OTSRYF vs KOTSRYF vs MAINTSRYF vs JNJTSRYF vs ABBVTSRYF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.